Additionally, Sun et al. detected EpCAM+ CTCs in 66.67% HCC patients and those with CTCs ≥ 2 per 7.5 mL (approximately 41%) showed higher tumor recurrence rate than patients with CTCs < 2 per 7.5 mL (70.6% versus 20.8%). This evidence concerns the gene EPCAM and hepatocellular carcinoma.